Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Oropharyngeal Neoplasms 3Myelodysplastic Syndromes 3Leukemia 3Mouth Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Gliosarcoma 2Carcinoma, Ovarian Epithelial 2Carcinoma 2Anemia, Refractory, with Excess of Blasts 2Adenocarcinoma of Lung 2Warts 1Vasculitis 1Urinary Bladder Neoplasms 1Spinal Cord Neoplasms 1Sarcoma, Synovial 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1

Interventions

plerixafor 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × NIH × Agammaglobulinemia × Clear all
NCT02231879 2023-04-07

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2/3 Completed
20 enrolled 10 charts

Agammaglobulinemia, Immunologic Deficiency Syndromes, Infections, Neutropenia, Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡